Similar articles

• Management of tuberculosis.

  Meissner PE, Coulter JB. Meissner PE, et al. N Engl J Med. 2001 Nov 15;345(20):1502. doi: 10.1056/NEJM200111153452017. N Engl J Med. 2001. PMID: 11794211 No abstract available.
• Alternatives to INH chemoprophylaxis.

  Sane SV, Sane NS, Thakker SV. Sane SV, et al. Indian Pediatr. 1995 Aug;32(8):935-7. Indian Pediatr. 1995. PMID: 8635847 No abstract available.
• [Molecular medicine and treatment of tuberculosis].

  Perel'man MI, Khomiakov IuN, Kiselev VI, Severin ES, Pal'tsev MA. Perel'man MI, et al. Probl Tuberk. 2001;(5):5-7. Probl Tuberk. 2001. PMID: 11588966 Russian. No abstract available.
• Considering the role of four months of rifampin in the treatment of latent tuberculosis infection.

  Reichman LB, Lardizabal A, Hayden CH. Reichman LB, et al. Am J Respir Crit Care Med. 2004 Oct 15;170(8):832-5. doi: 10.1164/rccm.200405-584PP. Epub 2004 Aug 5. Am J Respir Crit Care Med. 2004. PMID: 15297274 Review. No abstract available.
• The tuberculosis pandemic--which way now?

  Zumla A, Mwaba P, Squire SB, Grange JM. Zumla A, et al. J Infect. 1999 Mar;38(2):74-9. doi: 10.1016/s0163-4453(99)90072-5. J Infect. 1999. PMID: 10342645 Review. No abstract available.